Caldwell Trust Co Sells 4,402 Shares of Astrazeneca Plc $AZN

Caldwell Trust Co trimmed its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 39.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,618 shares of the company’s stock after selling 4,402 shares during the quarter. Caldwell Trust Co’s holdings in Astrazeneca were worth $1,305,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of AZN. Cornerstone Wealth Group LLC acquired a new stake in shares of Astrazeneca in the first quarter worth about $220,000. Border to Coast Pensions Partnership Ltd acquired a new position in shares of Astrazeneca during the 1st quarter valued at about $398,270,000. Pictet Asset Management Holding SA acquired a new position in shares of Astrazeneca during the 1st quarter valued at about $675,263,000. ABN AMRO Bank N.V. increased its holdings in shares of Astrazeneca by 32,441.5% during the 1st quarter. ABN AMRO Bank N.V. now owns 2,445,171 shares of the company’s stock valued at $482,158,000 after acquiring an additional 2,437,657 shares during the last quarter. Finally, Value Partners Investments Inc. bought a new position in shares of Astrazeneca in the 1st quarter valued at approximately $11,331,000. 20.35% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Barclays restated a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Weiss Ratings downgraded shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 18th. Finally, DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Astrazeneca currently has an average rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Stock Performance

AZN opened at $188.58 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The stock’s 50 day moving average price is $184.66 and its two-hundred day moving average price is $187.05. The firm has a market capitalization of $292.47 billion, a P/E ratio of 28.32, a price-to-earnings-growth ratio of 1.64 and a beta of 0.25. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. On average, equities analysts forecast that Astrazeneca Plc will post 9.39 earnings per share for the current year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.